Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 - 30 (cancelled)

31 (currently amended): A method for treating an ophthalmic disorder in a mammal, said method comprising administering to the eye of said mammal a lipid formulation, said lipid formulation comprising:

a lipid phase, said lipid phase comprising a phospholipid ~~neutral lipid~~ and a modifying agent, wherein said modifying agent is a member selected from the group consisting of cationic lipids and mucoadhesive compounds;

an aqueous phase; and

a therapeutic agent, wherein said therapeutic agent in said lipid formulation is useful for treating said ophthalmic disorder;

wherein said lipid formulation comprises about 0.001 to about 10.000 wt % of said lipid phase and about 90.000 wt % to about 99.999 wt % of said aqueous phase, and wherein said lipid phase comprises 0.01 to 10 wt% phospholipid, 0.1 to 10 wt % modifying agent and 0.1 to 10 wt% antioxidant.

32 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is post-operative pain.

33 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is ocular inflammation.

34 (currently amended): The method in accordance with claim 33, wherein said ocular inflammation results from a member selected from the group consisting of iritis,

conjunctivitis, seasonal allergic conjunctivitis, acute and chronic endophthalmitis, anterior uveitis, uveitis associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis, ~~masquerade syndromes including~~ ocular lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy, corneal abrasion and blood-aqueous barrier disruption.

35 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is post-operative ocular inflammation.

36 (original): The method in accordance with claim 35, wherein said post-operative ocular inflammation results from a member selected from the group consisting of photorefractive keratectomy, cataract removal surgery, intraocular lens implantation and radial keratotomy.

37 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is a fungal or bacterial infection.

38 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is herpes ophthalmicus.

39 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is endophthalmitis.

40 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is intraocular pressure.

41 (original): The method in accordance with claim 31, wherein said therapeutic agent is diclofenac.

42 (original): The method in accordance with claim 41, wherein said diclofenac is diclofenac sodium.

43 (currently amended): A method for treating or preventing ocular inflammation, paracentesis-induced miosis, cystoid macular edema and mydriasis, said method

comprising administering a therapeutically effective amount of one or more non-steroidal anti-inflammatory drugs encapsulated or contained within a liposome formulation, said liposome formulation comprising 0.001 to 10.000 wt% lipid phase, and 90.000 to 99.999 wt% aqueous phase, wherein said lipid phase comprises 0.01 to 10 wt% phospholipid, 0.1 to 10%modifying agents and 0.1 to 10 wt% antioxidant.

44 (original): The method in accordance with claim 43, wherein said liposome formulation is applied topically, resulting in the transcorneal or transscleral passage or introduction of one or more non-steroidal anti-inflammatory drugs into the eye.

45 (currently amended): The method in accordance with claim 43, wherein said lipid phase further comprises 0.0 to 90.0 wt% of one or more active agents~~, 10.0 to 100.0 wt% phospholipid, 0.0 to 20.0 wt% antioxidant, and 0.0 to 20% modifying agents~~; and said aqueous phase comprises 0.0 to 10.0 wt% one or more active agents, 0.0 to 5.0 wt% anti-microbial preservative, and 90.0 to 100.0 wt% aqueous solution.

46 (original): The method in accordance with claim 45, wherein said active agent(s) are non-steroidal anti-inflammatory drugs.

47 (original): The method in accordance with claim 46, wherein said non-steroidal anti-inflammatory drugs are selected from the group consisting of ketoprofen, flurbiprofen, ibuprofen, diclofenac, ketorolac, nepafenac, amfenac and suprofen.

48 (original): The method in accordance with claim 47, werein said non-steroidal anti-inflammatory drug is diclofenac.

49 (currently amended): The method in accordance with claim 43, wherein said ocular inflammation is a symptom of iritis, conjunctivitis, seasonal allergic conjunctivitis, post-operative inflammation, acute and chronic endophthalmitis, anterior uveitis, uveitis associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis, ~~masquerade~~

~~syndromes including~~ ocular lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy, corneal abrasion, blood-aqueous barrier disruption or ocular trauma.

50 (original): The method in accordance with claim 49, wherein said post-operative inflammation is caused by photorefractive keratectomy, cataract removal surgery, intraocular lens implantation or radial keratotomy.

51 - 52 (cancelled)